Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroFuse-020: MK-2870 vs Treatment of Physician's Choice in Recurrent/Metastatic Cervical Cancer
jRCT2031240201Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in Cervical Cancer (CC) (2 arms), sponsored by Merck & Co. Started Nov 2024; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2031240201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240201.